What happens when you stop tirzepatide: the SURMOUNT-4 data, plain

"Do I have to take this forever?" is the single most common question people ask before starting tirzepatide. The honest answer is "probably, if you want to keep the weight off." The evidence comes from SURMOUNT-4, published in JAMA in 2023. Almost every commercial site talks around it. Here is what the trial actually shows.

The trial design, briefly

SURMOUNT-4 (Aronne et al., JAMA 2023) enrolled 670 adults with BMI over 30 (or 27 with comorbidities). Everyone did a 36-week lead-in where they received tirzepatide 15 mg weekly. Average weight loss during the lead-in was 20.9% from baseline. That is the headline SURMOUNT-1 number, replicated.

At week 36, participants were randomized into two groups. Group A continued tirzepatide 15 mg for another 52 weeks. Group B was switched to placebo for the same period. Neither group knew which arm they were in.

The numbers

Group A (continued tirzepatide) at week 88: additional 5.5% weight loss from week 36. So a cumulative ~26% loss from baseline over 88 weeks.

Group B (switched to placebo) at week 88: regained 14 percentage points on average, ending at only ~7% below baseline. In plain terms: they lost two-thirds of their initial weight loss in the year after stopping the drug.

The regain curve is not linear. Most of the regain happened in the first 20 weeks after switching. By week 56 the curve flattens, but at a weight much higher than the week-36 low.

Why this happens

GLP-1 and GIP agonism suppress appetite by slowing gastric emptying, altering hypothalamic hunger signals, and reducing food-reward activity in the brain. When you stop the drug, all three mechanisms return to baseline within 4 to 6 weeks. The drug's half-life is 5 days, so it is out of your system by week 4, and the receptor activity returns shortly after.

Nothing about the drug rewires hunger permanently. It adjusts the signal while it is present. Remove the signal, the old signal returns.

What the drug also does not do: reduce the total number of fat cells. When you lose weight on tirzepatide, the fat cells shrink, not disappear. After stopping, those cells are still there and still biologically primed to refill.

What the marketing skips

You will see commercial sites frame SURMOUNT-4 as "tirzepatide continues to work long-term." That is true. It does. What they skip is that "long-term" means you are still taking it. There is no 12-week course that resets your metabolism. That narrative does not exist in the data.

Some honest framings that should appear more often:

• Tirzepatide is a maintenance drug, not a cure
• Coming off means planning for regain, not avoiding it
• If cost is the reason to stop, lower the dose before stopping entirely
• If side effects are the reason to stop, a different GLP-1 (semaglutide, usually) may be better tolerated

What maintenance actually looks like

A realistic long-term protocol based on what we see across Panya-reviewed clinics:

• Months 1-3: standard ramp to target dose (typically 10 or 15 mg)
• Months 4-12: target dose, weekly. Weight-loss phase.
• Months 12+: maintenance. Two common paths:

1. Keep at target dose indefinitely. Most predictable. Most expensive. 2. Step down to the lowest dose that holds your weight (often 5 mg). Lower cost, similar outcome for many patients.

The step-down path is underused because most prescribers default to "keep what works." It is worth asking about if cost matters and you have held your target weight for 3+ months.

What about coming off entirely?

Some patients do come off. It is not a failure; it is a choice. The cases where it makes sense:

• You lost 5 to 10 kg and your BMI is back under 25, you are active, and you have the dietary habits to defend against regain
• Pregnancy (coming off is required, not optional)
• Side effects that do not resolve after dose adjustment
• Cost becomes prohibitive and you accept the tradeoff

If you stop, the regain is mechanical. Expect it. Build an exercise and eating framework that assumes you will regain 30 to 60 percent of what you lost. The research says more, but self-selected real-world patients with better baseline habits regain less than trial participants. Your mileage varies.

The key question for anyone starting

Before you begin, answer honestly: "Am I willing to budget for 10 to 30 USD per week for the next 5 to 10 years?" If the answer is no, plan your off-ramp before you start. Decide in advance what weight you would hold at, what exercise pattern you commit to, and what your step-down schedule would look like.

This is the conversation most clinicians do not have with you on the first visit. Have it with yourself.

What Panya recommends

When you take our quiz, the email unlock names a vendor plus notes on that vendor's maintenance-dose pricing (if we have it). If maintenance cost is the constraint, we surface the cheapest quality option in your region. Our geographic arbitrage panel shows what 5 mg monthly looks like across markets; it is often 40-50 percent of the 15 mg cost because the drug is billed per mg.

If you are already on tirzepatide and thinking about stopping, the most useful thing you can do is speak to the prescriber who started you. If you want an independent read on whether your current vendor is charging fairly, our rubric can score them without naming them.

---

Citations: Aronne LJ et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA 2023;331(1):38-48. Also: Jastreboff et al. NEJM 2022 (SURMOUNT-1); Eli Lilly prescribing information for Mounjaro and Zepbound.